USPTO serial 98197383
MAPKIT
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- RENNEKER, CHRISTOPHER JOHN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with MAPKIT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Francisco, CA
San Francisco, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jordan A. LaVine
Jordan A. LaVine FLASTER GREENBERG PCSUITE 100, 100 FRONT STREETCONSHOHOCKEN, PA 19428UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Business data collection and analysis services in the field of healthcare, namely, aggregating, organizing and compiling of information, data, statistics, insights, metrics, profiles, analytics and intelligence on healthcare industry demographics, practitioner demographics, patient demographics, patient therapies and treatments, prescriptions, patient flows and referral pathways, disease demographics, care demographics, lab data, clinical study and trial demographics, healthcare behaviors, costs, and outcomes, payer data, and scientific publications, all of the foregoing excluding psychedelic medicines and therapies; business consulting and analysis services regarding information, data, statistics, insights, metrics, profiles, analytics and intelligence on healthcare industry demographics, practitioner demographics, patient demographics, patient therapies and treatments, prescriptions, patient flows and referral pathways, disease demographics, care demographics, lab data, clinical study and trial demographics, healthcare behaviors, costs, and outcomes, payer data, and scientific publications, all of the foregoing excluding psychedelic medicines and therapies; Providing business information in the field of the healthcare and life sciences industries, all of the foregoing excluding psychedelic medicines and therapies; Business consulting services to businesses in the healthcare and life sciences industries, all of the foregoing excluding psychedelic medicines and therapies | ACTIVE | — |
| 042 | Platform-as-a-service (PaaS) featuring computer software platforms that allows organizations and stakeholders in healthcare viewing of a database with information, data, statistics, insights, metrics, profiles, analytics and intelligence on healthcare industry demographics, practitioner demographics, patient demographics, patient therapies and treatments, prescriptions, patient flows and referral pathways, disease demographics, care demographics, lab data, clinical study and trial demographics, healthcare behaviors, costs, and outcomes, payer data, and scientific publications, all of the foregoing excluding psychedelic medicines and therapies; platform-as-a-service (PaaS) featuring computer software platforms that allows organizations and stakeholders in healthcare the ability to model patient journeys, pathways, and care programs, all of the foregoing excluding psychedelic medicines and therapies; computer services, namely, database development services, namely, configuration and customization of databases containing information, data, statistics, insights, metrics, profiles, analytics and intelligence healthcare industry demographics, practitioner demographics, patient demographics, patient therapies and treatments, prescriptions, patient flows and referral pathways, disease demographics, lab data, care demographics, clinical study and trial demographics, healthcare behaviors, costs, and outcomes, payer data, and scientific publications, all of the foregoing excluding psychedelic medicines and therapies; platform-as-a-service (paas) featuring computer software platforms that allow the viewing of market access insights to the life sciences industry, provide business solutions that unify pharmaceutical sales, operations, and marketing data, and provide data intelligence that aids with effective targeting, messaging, and initiatives driving sales performance, all of the foregoing excluding psychedelic medicines and therapies; Design, development and implementation of computer software for the healthcare and life sciences industry, namely, the design and development of cloud-based and application-based software for monitoring, marketing, and delivering products in the healthcare and life sciences industry, all of the foregoing excluding psychedelic medicines and therapies; Consulting services in the fields of selection, implementation and use of computer hardware and software systems for others in the health care and life science industries, all of the foregoing excluding psychedelic medicines and therapies; Business technology software consultation services in the health care and life science industries, all of the foregoing excluding psychedelic medicines and therapies; Software development and product development consulting in the field of the health care and life science industries, all of the foregoing excluding psychedelic medicines and therapies | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 31, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 31, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 27, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 2, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 2, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 12, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 24, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 22, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 22, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 22, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 22, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 22, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 22, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 22, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 22, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 21, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 21, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 21, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 21, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 14, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 14, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 14, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 14, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 1, 2023 | TAEA | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | — |
| Nov 1, 2023 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Oct 11, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 29, 2023 | NWAP | NEW APPLICATION ENTERED | — |